Gross-to-net adjustments have doubled in the past seven years and are squeezing profit margins as distance grows between drug list prices and their net prices after rebates and other reductions. A 1% improvement in GTN can mean millions to the bottom line.
Anaplan is a cloud-native enterprise SaaS company that empowers global organizations to orchestrate business performance and execute digital transformation with confidence and agility. 2021 AMER Partner of the Year
years of partnership
Our clients include pharmaceutical companies, big or small, focusing on branded, specialty, and generic segments. Being able to understand, explain, and accurately forecast GTN adjustments is critical to the finance function of commercial pharmaceutical organizations.
In one centralized solution, capture the impact of market events to forecast in-market volumes; model pricing changes by brand and SKU; perform pre-/post-deal analytics and forecast and measure contract performance; incorporate rebate assumptions; and forecast channel mix and rebates by channel across Commercial, Part D, and Medicaid. Quickly apply changes to methodologies for forecasting GTN.
Simplify gross-to-net complications and confidently model all assumptions around distributor agreements, complex contract terms, and all rebates, chargebacks, and deductions.